These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Hepatotoxicity associated with dietary supplements containing anabolic steroids.
    Author: Kafrouni MI, Anders RA, Verma S.
    Journal: Clin Gastroenterol Hepatol; 2007 Jul; 5(7):809-12. PubMed ID: 17509944.
    Abstract:
    BACKGROUND & AIMS: The aim of this article was to re-emphasize the hepatotoxicity associated with the use of anabolic androgenic steroids and to highlight the marketing and sale of anabolic androgenic steroids as dietary supplements. METHODS: This was a case series of 2 patients who developed a cholestatic liver panel after consumption of anabolic androgenic steroids. A detailed Pubmed/Medline search was performed to research this topic. RESULTS: We present 2 young men who developed significant cholestatic liver injury after consumption of anabolic androgenic steroids. This was associated with considerable morbidity, although both patients recovered without the need for a liver transplant. Both of these anabolic androgenic steroids were being marketed as dietary supplements. CONCLUSIONS: Despite being classified as class III controlled substances, anabolic androgenic steroids are still a cause for serious hepatotoxicity in the United States. Some of these anabolic androgenic steroids are being marketed as dietary supplements. Although the Food and Drug Administration is making concerted efforts to regulate this, increased vigilance also is required from the medical profession.
    [Abstract] [Full Text] [Related] [New Search]